DTIL insider transaction filings
PRECISION BIOSCIENCES INC — 49 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-05. Screen DTIL transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-05 | 4 | Brown Melinda — Director | Grant/award (A): 20,979 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Frankel Stanley — Director | Grant/award (A): 20,979 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Germano Geno J — Director | Grant/award (A): 20,979 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Pire Shari Lisa — Director | Grant/award (A): 20,979 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Buehler Kevin — Director | Grant/award (A): 20,979 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | SMITH J. JEFFERSON — Chief Research Officer | Grant/award (A): 57,389 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Scimeca Dario — General Counsel and Secretary | Grant/award (A): 107,604 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Kelly John Alexander — Chief Financial Officer | Grant/award (A): 193,688 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Amoroso Michael — President and CEO, Director | Grant/award (A): 573,888 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Buehler Kevin — Director | Option exercise (M): 21,000 · Option exercise (M): 21,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Frankel Stanley — Director | Option exercise (M): 21,000 · Option exercise (M): 21,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Brown Melinda — Director | Option exercise (M): 21,000 · Option exercise (M): 21,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Pire Shari Lisa — Director | Option exercise (M): 21,000 · Option exercise (M): 21,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | Germano Geno J — Director | Option exercise (M): 21,000 · Option exercise (M): 21,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Amoroso Michael — President and CEO, Director | Option exercise (M): 67,797 @ $0 · Sale (S): 20,559 @ $3.84 · Option exercise (M): 67,797 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Kelly John Alexander — Chief Financial Officer | Option exercise (M): 27,584 @ $0 · Sale (S): 8,149 @ $3.84 · Option exercise (M): 27,584 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Scimeca Dario — General Counsel and Secretary | Option exercise (M): 16,667 @ $0 · Sale (S): 4,925 @ $3.84 · Option exercise (M): 16,667 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | SMITH J. JEFFERSON — Chief Research Officer | Option exercise (M): 16,667 @ $0 · Sale (S): 4,925 @ $3.84 · Option exercise (M): 16,667 (derivative) @ $0 | EDGAR |
| 2026-01-22 | 4 | Amoroso Michael — President and CEO, Director | Option exercise (M): 8,888 · Option exercise (M): 37,069 · Option exercise (M): 69,421 · Sale (S): 34,799 @ $4.17 · Option exercise (M): 8,888 (derivative) @ $0 · Option exercise (M): 37,069 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-22 | 4 | Scimeca Dario — General Counsel and Secretary | Option exercise (M): 1,978 @ $0 · Option exercise (M): 8,425 @ $0 · Option exercise (M): 14,908 @ $0 · Sale (S): 8,854 @ $4.03 · Option exercise (M): 1,978 (derivative) @ $0 · Option exercise (M): 8,425 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-22 | 4 | Kelly John Alexander — Chief Financial Officer | Option exercise (M): 3,888 · Option exercise (M): 13,900 · Option exercise (M): 26,575 · Sale (S): 15,213 @ $4.03 · Option exercise (M): 3,888 (derivative) @ $0 · Option exercise (M): 13,900 (derivative) @ $0 · +1 more | EDGAR |
| 2026-01-22 | 4 | SMITH J. JEFFERSON — Chief Research Officer | Option exercise (M): 2,500 · Option exercise (M): 10,447 · Option exercise (M): 16,219 · Sale (S): 10,200 @ $4.03 · Option exercise (M): 2,500 (derivative) @ $0 · Option exercise (M): 10,447 (derivative) @ $0 · +1 more | EDGAR |
| 2025-12-17 | 4 | Germano Geno J — Director | Purchase (P): 3,000 @ $4.72 | EDGAR |
| 2025-12-17 | 4 | Frankel Stanley — Director | Purchase (P): 2,700 @ $4.70 | EDGAR |
| 2025-12-17 | 4 | Brown Melinda — Director | Purchase (P): 1,381 @ $4.97 | EDGAR |
| 2025-11-04 | 4 | Kelly John Alexander — Chief Financial Officer | Option exercise (M): 3,605 @ $0 · Sale (S): 1,303 @ $6.49 · Option exercise (M): 3,605 (derivative) @ $0 | EDGAR |
| 2025-11-04 | 4 | Scimeca Dario — General Counsel and Secretary | Option exercise (M): 1,835 @ $0 · Sale (S): 665 @ $6.49 · Option exercise (M): 1,835 (derivative) @ $0 | EDGAR |
| 2025-11-04 | 4 | Amoroso Michael — President and CEO, Director | Option exercise (M): 9,444 @ $0 · Sale (S): 3,409 @ $6.49 · Option exercise (M): 9,444 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | Frankel Stanley — Director | Purchase (P): 2,700 @ $4.97 | EDGAR |
| 2025-09-24 | 4 | Brown Melinda — Director | Purchase (P): 1,400 @ $4.89 | EDGAR |
| 2025-07-08 | 4 | Kelly John Alexander — Chief Financial Officer | Sale (S): 14,827 @ $4.26 | EDGAR |
| 2025-06-27 | 4 | Brown Melinda — Director | Purchase (P): 1,682 @ $4.14 | EDGAR |
| 2025-06-27 | 4 | Buehler Kevin — Director | Purchase (P): 5,076 @ $4.16 | EDGAR |
| 2025-06-04 | 4 | Buehler Kevin — Director | Option exercise (M): 9,826 · Option exercise (M): 9,826 (derivative) @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Germano Geno J — Director | Option exercise (M): 9,826 · Option exercise (M): 9,826 (derivative) @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Pire Shari Lisa — Director | Option exercise (M): 9,826 · Option exercise (M): 9,826 (derivative) @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Frankel Stanley — Director | Option exercise (M): 9,826 · Option exercise (M): 9,826 (derivative) @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Brown Melinda — Director | Option exercise (M): 9,826 · Option exercise (M): 9,826 (derivative) @ $0 · Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | SMITH J. JEFFERSON — Chief Research Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Scimeca Dario — General Counsel and Secretary | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Amoroso Michael — President and CEO, Director | Grant/award (A): 203,390 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Kelly John Alexander — Chief Financial Officer | Grant/award (A): 82,750 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | Brown Melinda — Director | Purchase (P): 1,839 @ $4.75 | EDGAR |
| 2025-03-28 | 4 | Buehler Kevin — Director | Purchase (P): 4,523 @ $4.67 | EDGAR |
| 2025-03-27 | 4 | Germano Geno J — Director | Purchase (P): 3,250 @ $5.30 | EDGAR |
| 2025-03-25 | 4 | Amoroso Michael — President and CEO, Director | Option exercise (M): 3,417 · Sale (S): 964 @ $5.56 · Option exercise (M): 3,417 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Scimeca Dario — General Counsel and Secretary | Option exercise (M): 919 · Sale (S): 272 @ $4.91 · Option exercise (M): 919 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | SMITH J. JEFFERSON — Chief Research Officer | Option exercise (M): 519 · Sale (S): 154 @ $4.91 · Option exercise (M): 519 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Kelly John Alexander — Chief Financial Officer | Option exercise (M): 1,702 · Option exercise (M): 1,702 (derivative) @ $0 | EDGAR |
Recent 8-K events — PRECISION BIOSCIENCES INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-17 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-11 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=DTIL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →